Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SIXA | 57.40 | -0.02 | -0.03% |
| ETC 6 Meridian Mega Cap Equity ETF (SIXA) | |||
| MAYT | 39.58 | -0.05 | -0.12% |
| AllianzIM U.S. Equity Buffer10 May ETF (MAYT) | |||
| IBMU | 25.15 | -0.07 | -0.28% |
| iShares iBonds Dec 2032 Term Muni Bond ETF (IBMU) | |||
| RYLG | 23.49 | -0.09 | -0.39% |
| Global X Russell 2000 Covered Call & Growth ETF (RYLG) | |||
| SLYG | 110.53 | -0.53 | -0.48% |
| State Street SPDR S&P 600 Small Cap Growth ETF (SLYG) | |||
A.I.dvisor indicates that over the last year, PLX has been loosely correlated with ABEO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then ABEO could also see price increases.
| Ticker / NAME | Correlation To PLX | 1D Price Change % | ||
|---|---|---|---|---|
| PLX | 100% | +11.28% | ||
| ABEO - PLX | 38% Loosely correlated | -3.35% | ||
| IOVA - PLX | 37% Loosely correlated | -1.10% | ||
| CTMX - PLX | 35% Loosely correlated | N/A | ||
| STOK - PLX | 31% Poorly correlated | -1.80% | ||
| SNDX - PLX | 31% Poorly correlated | -0.63% | ||
More | ||||
a developer of recombinant therapeutic proteins
Industry Biotechnology
PLX saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 76 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 58 cases where PLX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for PLX just turned positive on November 10, 2026. Looking at past instances where PLX's MACD turned positive, the stock continued to rise in 35 of 43 cases over the following month. The odds of a continued upward trend are 81%.
PLX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLX advanced for three days, in 207 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The 10-day moving average for PLX crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PLX broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PLX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 32 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 58 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.866) is normal, around the industry mean (3.498). P/E Ratio (10.583) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.697) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.